Ascentage pharma announces a new drug application for its novel bcl-2 inhibitor lisaftoclax accepted and recommended priority review designation by cde of china nmpa

Rockville, md. and suzhou, china , nov. 17, 2024 /prnewswire/ -- ascentage pharma (6855.hk), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that a new drug application (nda) for its inhouse developed investigational novel bcl-2 selective inhibitor, lisaftoclax (apg-2575), for the treatment of patients with relapsed or refractory (r/r) chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll) has been accepted and recommended the priority review designation by the center for drug evaluation (cde) of china's national medical products administration (nmpa).
CDE Ratings Summary
CDE Quant Ranking